Глобальный рынок диагностики рака легких – тенденции отрасли и прогноз до 2031 года

Анализ и размер рынка диагностики рака легких

Раннее выявление является важной особенностью рынка диагностики рака легких, предлагая возможность выявления рака легких на начальных стадиях, когда лечебные вмешательства наиболее эффективны. Благодаря передовым программам скрининга и диагностическим тестам, таким как низкодозная КТ и молекулярное тестирование, поставщики медицинских услуг могут выявлять рак легких у лиц с высоким риском или у тех, у кого проявляются ранние симптомы. Раннее выявление улучшает результаты лечения пациентов, позволяя своевременно начинать лечение и сокращая расходы на здравоохранение, связанные с управлением заболеванием на поздней стадии.

Например,

По данным Национального центра биотехнологической информации (NCBI), хирургическая резекция немелкоклеточного рака легких (НМРЛ) на ранней стадии может обеспечить благоприятные показатели 5-летней выживаемости до 70%. Однако у большинства пациентов диагностируется заболевание на поздней стадии, где показатели выживаемости остаются низкими, несмотря на достижения в онкологическом лечении. В отчете NCBI подчеркивается статистика Великобритании, показывающая резкую разницу в показателях 1-летней выживаемости между пациентами с раком легких на стадии I (81-85%) и стадии IV (15-19%), что подчеркивает критическую необходимость в улучшенных стратегиях раннего выявления для улучшения результатов лечения пациентов и снижения показателей смертности.

Объем мирового рынка диагностики рака легких в 2023 году оценивался в 2,97 млрд долларов США, а к 2031 году, по прогнозам, он достигнет 8,59 млрд долларов США, при среднегодовом темпе роста 14,2% в прогнозируемый период с 2024 по 2031 год. Помимо аналитических данных о рыночных сценариях, таких как рыночная стоимость, темпы роста, сегментация, географический охват и основные игроки, рыночные отчеты, подготовленные Data Bridge Market Research, также включают в себя углубленный экспертный анализ, эпидемиологию пациентов, анализ перспективных направлений, анализ цен и нормативно-правовую базу.

Объем и сегментация рынка диагностики рака легких      

Market Definition

Lung cancer is a malignant tumor that originates in the cells of the lungs, typically in the lining of the bronchi or the alveoli. It is primarily caused by long-term exposure to substances such as cigarette smoke, asbestos, and air pollution. Lung cancer is categorized into two main types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), each with distinct characteristics and treatment approaches. Symptoms may include persistent cough, chest pain, shortness of breath, coughing up blood, and unexplained weight loss. Lung cancer is one of the most common cancers worldwide and a leading cause of cancer-related mortality.

Lung Cancer Diagnostics Market Dynamics

Drivers

• Growing Technological Advancements Enhances Reliability of Diagnostic Methods

Innovations in imaging technologies, such as computed tomography (CT) scans and positron emission tomography (PET) scans, enable early detection of lung nodules and metastases. Advancements in molecular diagnostics, including next-generation sequencing (NGS) and liquid biopsy techniques, facilitate the identification of specific genetic mutations and biomarkers associated with lung cancer. These technological breakthroughs improve diagnostic accuracy and enable personalized treatment strategies tailored to individual patients, thereby driving the demand for advanced diagnostic tools and services in the lung cancer diagnostics market.

For Instance,

In October 2023, DELFI Diagnostics' launch of FirstLook Lung represents a significant advancement in lung cancer diagnostics. While introducing a routine blood test for lung cancer screening, FirstLook Lung offers a non-invasive and accessible method for early detection. This innovative technology utilizes molecular diagnostics and biomarker analysis to enhance the accuracy of screening, aligning with the trend of technological advancements driving the lung cancer diagnostics market. The availability of such a convenient and precise screening tool improves early detection rates and underscores the importance of leveraging cutting-edge technologies to combat lung cancer effectively.

• Growing Awareness of Early Detection and Screening for Lung Cancer Leads to Better Disease Management

As public education campaigns raise awareness about risk factors such as smoking and environmental pollutants, individuals are more expected to seek preventive healthcare measures, including regular screenings. Advocacy efforts by healthcare organizations and patient groups further amplify awareness, prompting healthcare providers to prioritize lung cancer screening and diagnosis in their practice. Growing awareness plays a pivotal role in driving the uptake of lung cancer diagnostics, ultimately contributing to better disease management and reduced mortality rates.

Opportunities

• Rising Aging Population Leads to Growing Demand of Specialized Diagnostic Solutions

As people age, their risk of developing lung cancer increases, driving the demand for diagnostic tests and screening programs tailored to this demographic. Additionally, older adults often experience comorbidities and may have unique healthcare needs, necessitating comprehensive diagnostic approaches that consider age-related factors. The growing aging population in many regions, particularly in developed countries, creates a steady demand for lung cancer diagnostics, offering opportunities for market expansion and the development of specialized diagnostic solutions targeting this demographic.

• Increasing Investments in Research and Development promotes the Demand for Scalable Screening Programs

Research and development investments fuel innovation, leading to the development of advanced diagnostic technologies and novel biomarkers for early detection and accurate diagnosis of lung cancer. As R&D efforts progress, there is potential for the introduction of more cost-effective and efficient diagnostic solutions, addressing the growing demand for accessible and scalable screening programs. Furthermore, collaborations between academia, industry, and government entities foster interdisciplinary approaches, accelerating the translation of research findings into clinical applications. Ultimately, these investments pave the way for improved patient outcomes, reduced healthcare burden, and enhanced strategies for combating lung cancer globally.

Restraints/Challenges

• High Costs Associated with Lung Cancer Diagnostics limits Diagnostic Procedures

Advanced diagnostic techniques such as molecular testing and imaging modalities can be expensive, placing financial burdens on patients and healthcare systems asuch as. These costs may deter individuals from seeking timely screenings or diagnostic tests, resulting in delayed diagnosis and poorer outcomes. Additionally, limited reimbursement coverage for certain diagnostic procedures further exacerbates the affordability issue, particularly for uninsured or underinsured populations.

• Stringent Regulatory Approval Delays Introduction of Innovative Diagnostic Solutions

The approval process poses a significant restraint on the lung cancer diagnostics market. Developing and commercializing new diagnostic tests and technologies for lung cancer requires extensive clinical validation and regulatory clearance, which can be time-consuming and resource-intensive. Delays in obtaining regulatory approval prolong the time to market entry, hindering the introduction of innovative diagnostic solutions. Moreover, the complexity of regulatory requirements may deter smaller companies with limited resources from pursuing development efforts, limiting the diversity and competitiveness of the market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global laboratory information management systems (LIMS) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In August 2022, F. Hoffmann-La Roche Ltd. launched the Digital LightCycler System, a cutting-edge digital PCR system aiding clinical researchers in comprehending cancer, genetic diseases, and infections. This system enhances DNA and RNA analysis precision, specifically tailored for oncology and infectious disease laboratories
• In October 2022, Quest Diagnostics embarking on a renewed collaboration with Decode Health, marking a new phase in their partnership. This endeavor has streamlined the development of diagnostic tests and identification of novel medication targets for diverse cancers, while also bolstering Quest Diagnostics' global footprint

Lung Cancer Diagnostics Market Scope

The market is segmented on the basis of product type, test type, cancer type, end user, and distribution channel. The growth amongst these segments will help you analyse meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Product Type

• Instruments
• Consumables and Accessories

Test Type

• Biomarkers Tests
• Imaging Test
• Biopsy
• Blood Test
• Others

Cancer Type

• Non-Small Cell Lung Cancer
• Small Cell Lung Cancer

End User

• Hospital
• Associated Labs
•  Independent Diagnostic Laboratories
• Diagnostic Imaging Centers
• Cancer Research Institutes
• Others

Distribution Channel

• Direct Tender
• Retail Sales

Lung Cancer Diagnostics Market Regional Analysis/Insights

The market is analyzed, and market size insights and trends are provided by country, product type, test type, cancer type, end user, and distribution channel, as referenced above.

Some countries covered in the market are the U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand,  Malaysia, Indonesia, Philippines, Vietnam, New Zealand, Taiwan and Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Oman, Bahrain, Qatar, Kuwait and Rest of Middle East and Africa.  

In North America, U.S. dominates in the market is anticipated due to a significant rise in awareness regarding early cancer detection and the importance of consultancy services. This heightened awareness has led to increased demand for advanced diagnostic technologies and services, driving market growth. Additionally, the U.S. boasts a robust healthcare infrastructure and a strong emphasis on research and development, further contributing to its leading position in cancer diagnostics. These factors collectively position the U.S. as a key player in shaping the future landscape of cancer diagnostics in North America.

In Europe, Germany is expected for growth in the lung cancer diagnostics market, driven by advancements in technology and the reliability of healthcare services. Germany's healthcare sector is renowned for its high standards and efficiency, which has instilled trust among patients and contributed to the adoption of diagnostic innovations. Additionally, the integration of healthcare data with portable devices enables personalized care and remote monitoring, enhancing diagnostic capabilities.

Раздел отчета по странам также содержит отдельные факторы, влияющие на рынок, и изменения в регулировании на внутреннем рынке, которые влияют на текущие и будущие тенденции рынка. Такие данные, как анализ цепочки создания стоимости сверху и снизу, технические тенденции и анализ пяти сил Портера, тематические исследования, являются некоторыми из указателей, используемых для прогнозирования рыночного сценария для отдельных стран. Кроме того, при предоставлении прогнозного анализа данных по странам учитываются наличие и доступность глобальных брендов и их проблемы, связанные с большой или малой конкуренцией со стороны местных и отечественных брендов, влияние внутренних тарифов и торговых путей.

Рост инфраструктуры здравоохранения, установленная база и проникновение новых технологий

Рынок также предоставляет вам подробный анализ рынка для каждой страны по росту расходов на здравоохранение для капитального оборудования, установленной базы различных видов продуктов для рынка, влияния технологий с использованием кривых жизненной линии и изменений в сценариях регулирования здравоохранения и их влияния на рынок. Данные доступны за исторический период 2016-2021 гг.

Анализ конкурентной среды и рынка диагностики рака легких

Конкурентная среда рынка содержит сведения о конкурентах. Включены сведения о компании, ее финансах, полученном доходе, рыночном потенциале, инвестициях в исследования и разработки, новых рыночных инициативах, глобальном присутствии, производственных площадках и объектах, производственных мощностях, сильных и слабых сторонах компании, запуске продукта, широте и широте продукта, доминировании приложений. Приведенные выше данные касаются только фокуса компаний на рынке.

Некоторые из основных игроков, работающих на рынке:

• F. HoffmannLa Roche Ltd. (Швейцария)
• Thermo Fisher Scientific Inc. (США)
• Эбботт (США)
• Quest Diagnostics Incorporated (США)
• Biodesix (США)
• Amoy Diagnostics Co., Ltd. (Китай)
• BioRad Laboratories, Inc. (США)
• Биокартис (Бельгия)
• Boditech Med Inc. (Южная Корея)
• Данахер (США)
• Vela Diagnostics (Сингапур)
• DiaSorin SpA (Италия)
• Exact Sciences UK, Ltd. (Великобритания)
• Guardant Health (США)
• LalPathLabs.com (Индия)
• LungLife AI, Inc. (США)
• МедГеном (Индия)
• Myriad Genetics, Inc. (США)
• Лаборатории NeoGenomics (США)
• Технология NanoString (США)
• Nanoentek (Южная Корея)
• Корпорация Онкоцит (США)
• PlexBio Co. Ltd. (Тайвань)
• QIAGEN (Германия)
• Siemens Healthcare GmbH (Германия)
• Veracyte, Inc. (США)

SKU-55789